fibrin and Endometriosis

fibrin has been researched along with Endometriosis* in 7 studies

Reviews

1 review(s) available for fibrin and Endometriosis

ArticleYear
Fibrinolysis: the key to new pathogenetic mechanisms.
    Current medicinal chemistry, 2008, Volume: 15, Issue:9

    The fibrinolytic system includes a broad spectrum of proteolytic enzymes with physiological and pathophysiological functions in several processes, such as haemostatic balance, tissue remodeling, tumor invasion, angiogenesis and reproduction. The main enzyme of the plasminogen activator system is plasmin, which is responsible for the degradation of fibrin into soluble degradation products. The activation of plasminogen into plasmin is mediated by two types of activators, urokinase-type plasminogen activator (uPA) and tissue-type plasminogen activator (tPA). The activity of both is regulated by specific plasminogen activator inhibitors (PAIs). There are 3 types of PAIs described so far but the most important fibrinolytic inhibitor in vivo is PAI type 1 (PAI-1). Among others, the presence of metabolic syndrome and the -675 4G/5G promoter polymorphism are known to be modulators of PAI-1 levels. Besides their fibrinolytic profile, plasmin and plasminogen activators are implicated in tissue proliferation and cellular adhesion, as they can proteolytically degrade the extracellular matrix and regulate the activation of both growth factors and matrix metalloproteinases. By all these means, the fibrinolytic system is also involved in physiological processes, and in pathological situations such as thrombosis, arteriosclerosis, endometriosis and cancer. PAI 1 has been studied in different settings with thrombotic pathophysiology, such as coronary artery disease and ischaemic stroke. Controversial results have been published and concerns about study designs or presence of confounders have been claimed to be responsible of them. Recently, its involvement in adverse thrombotic events related to the modern drug-eluting coronary stents has renewed the interest of its study. PAI-1 also plays an important role in signal transduction, cell adherence, and migration. Indeed, studies of several types of cancers, including breast cancer, have shown that increased uPA and PAI-1 levels are associated with aggressive tumor behavior and poor prognosis. Endometriosis is defined by the presence of endometrial glands and stroma outside the uterus with marked ability to attach and invade the peritoneum. It is one of the most frequent benign gynecological diseases that affect women with pelvic pain or infertility during their reproductive age. Immune system disorders, genetic predisposition, altered peritoneal environment and endometrial alterations are believed to increase the susceptib

    Topics: Coronary Artery Disease; Endometriosis; Female; Fibrin; Fibrinolysin; Fibrinolysis; Humans; Matrix Metalloproteinases; Neoplasms; Plasminogen; Plasminogen Activators; Plasminogen Inactivators; Tissue Plasminogen Activator; Urokinase-Type Plasminogen Activator

2008

Other Studies

6 other study(ies) available for fibrin and Endometriosis

ArticleYear
The effect of endometriosis on placental histopathology and perinatal outcome in singleton live births resulting from IVF.
    Reproductive biomedicine online, 2022, Volume: 45, Issue:4

    Does endometriosis have an effect on the placental histopathology pattern and perinatal outcome in singleton live births resulting from IVF treatment?. Retrospective cohort study evaluating the data on all live births following IVF treatment between 2009 and 2017 at one university-affiliated tertiary hospital. All patients had placentas sent for full gross and histopathology assessment, irrespective of complication status or delivery mode. The primary outcomes of the study included anatomical, inflammation, vascular malperfusion and villous maturation placental disorders. The secondary outcomes included fetal, maternal, perinatal and delivery complications. A multivariate logistic model was used to adjust the results for confounding factors potentially associated with significant placental characteristics.. A total of 1057 live births were included in the final analysis and were allocated to the group of women with endometriosis (n = 75) and those without (n = 982). After adjustment for confounding factors, endometriosis was found to be significantly associated with acute chorioamnionitis with moderate to severe maternal (odds ratio [OR] 2.2, 95% confidence interval [95% CI] 1.1-4.6) and fetal (OR 4.9, 95% CI 1.8-13.1) inflammatory response, placenta previa (OR 3.1, 95% CI 1.2-7.8), subchorionic fibrin deposition (OR 3.4, 95% CI 1.2-9.1), intervillous thrombosis (OR 3.4, 95% CI 1.5-8.1), and fetal vascular malperfusion (OR 5.1, 95% CI 1.4-18.1), as well as with preterm birth (OR 2.5, 95% CI 1.4-4.7).. Endometriosis has a significant impact on the placental histopathology and is associated with a higher incidence of preterm birth.

    Topics: Endometriosis; Female; Fertilization in Vitro; Fibrin; Humans; Infant, Newborn; Live Birth; Placenta; Placenta Diseases; Pregnancy; Premature Birth; Retrospective Studies

2022
Fibronectin Molecular Status in Plasma of Women with Endometriosis and Fertility Disorders.
    International journal of molecular sciences, 2021, Oct-22, Volume: 22, Issue:21

    The diagnosis of endometriosis and fertility disorders is difficult; therefore, it is necessary to look for reliable biomarkers. Analysis of the molecular status of fibronectin as a key player in repair and wound healing processes, as well as in coagulation and fibrinolysis pathways, is justified. ELISA and SDS-agarose immunoblotting were applied to determine the fibronectin concentration and presence and occurrence of soluble FN-fibrin complexes in the blood plasma of women with endometriosis (n = 38), fertility disorders (n = 28) and the healthy group (n = 25). The concentration of fibronectin in the blood plasma of women with endometriosis (292.61 ± 96.17 mg/L) and fertility disorders (287.53 ± 122.68 mg/L) was significantly higher than in the normal group (226.55 ± 91.98 mg/L). The presence of FN-fibrin complexes of 750, 1000, 1300, 1600 and 1900 kDa in the plasma of women with endometriosis and fertility disorders was shown. The presence of FN-fibrin complexes with a molecular mass of more than 1300 kDa in women with endometriosis and infertility and the complete absence of these complexes in healthy women may indicate an increased and chronic activation of coagulation mechanisms in these patients. The presence of complexes of high molecular mass may be one of the biomarkers of fertility disorders in women.

    Topics: Adult; Biomarkers; Endometriosis; Female; Fibrin; Fibrin Fibrinogen Degradation Products; Fibronectins; Humans; Infertility, Female; Middle Aged; Plasma

2021
Fibrin clot properties among women with endometriosis and the impact of ovarian stimulation.
    Reproductive biomedicine online, 2021, Volume: 43, Issue:1

    Is there a difference in fibrin clot phenotype in women with endometriosis before and after ovarian stimulation?. Prospective study including 73 infertile women in two age-matched groups: (i) with confirmed endometriosis (n = 29); (ii) without endometriosis (n = 44). Assessments of plasma fibrin clot permeability (K. Endometriosis was associated with increased thrombin generation, reflected by both higher F1+2 (+96.1%, P = 0.005) and ETP (+14.2%, P = 0.014) along with unfavourably altered fibrin clot properties represented by lower K. Endometriosis is associated with the prothrombotic fibrin clot phenotype and increased thrombin generation. Ovarian stimulation favourably alters fibrin clot properties and leads to comparable pregnancy outcomes to those in women without endometriosis.

    Topics: Adult; Endometriosis; Female; Fibrin; Fibrin Clot Lysis Time; Humans; Ovulation Induction; Prospective Studies; Thrombosis

2021
Letrozole stimulates the growth of human endometrial explants cultured in three-dimensional fibrin matrix.
    Fertility and sterility, 2009, Volume: 91, Issue:5 Suppl

    To investigate the effects of an aromatase inhibitor, letrozole, on the growth of human endometrium in a three-dimensional fibrin matrix model of endometriosis.. Experimental study of human endometrial biopsies in a three-dimensional fibrin matrix culture system.. Academic research center.. Eight normal women with benign gynecologic problems.. Endometrial biopsy samples were washed, cut into small pieces, and placed between two layers of fibrin gel in the presence or absence of letrozole in the culture medium. Tissue changes were assessed by histological and immunohistochemical staining using an inverted microscope, image analysis, and a semiquantitative scoring system.. Stromal and epithelial cell outgrowth into the fibrin matrix and angiogenesis comprising endothelial cell invasion of the matrix.. Letrozole (0.1 micromol/L, 1 micromol/L, and 10 micromol/L) exerted a significant growth stimulation effect on endometrial tissue in this model.. In contrast to our expectations, letrozole stimulated growth of normal human endometrium in an in vitro model of endometriosis. Normal endometrium may respond differently than endometriotic lesions to therapeutic agents. Our findings should be kept in mind when considering future research to explore new clinical treatments for endometriosis.

    Topics: Aromatase Inhibitors; Cell Culture Techniques; Cell Division; Dose-Response Relationship, Drug; Endometriosis; Endometrium; Female; Fibrin; Humans; Hysterectomy; Letrozole; Nitriles; Premenopause; Triazoles

2009
Genetic polymorphism in the fibrinolytic system and endometriosis.
    Obstetrics and gynecology, 2006, Volume: 108, Issue:1

    Although most women experience retrograde menses during their reproductive life, endometriosis develops only in a small percentage. We hypothesized that persistence of a fibrin matrix in peritoneal pockets, as a result of hypofibrinolysis, could allow menstrually deposited endometrial fragments to initiate endometriosis. Fibrinolysis is modulated by several factors, and polymorphisms in the plasminogen activator inhibitor-1 (PAI-1) gene are considered to be one of the important determinants. The objective of this study was to evaluate PAI-1 genotypes in a group of women with or without endometriosis.. In 118 women (75 with laparoscopically confirmed endometriosis and 43 controls), genomic DNA was extracted from blood and the PAI-1 promoter genotype was determined by polymerase chain reaction amplification of DNA using specific primers for the 4G or 5G allele followed by gel electrophoresis. A portion of the polymerase chain reaction product was purified and sequenced to confirm the gel electrophoresis results.. Endometriosis was more likely in patients with 4G/5G (odds ratio 38; 95% confidence interval [CI] 6-229) or 4G/4G (odds ratio 441; 95% CI 53-3,694) compared with 5G/5G PAI-1 genotype. Fifty-two of 75 women with endometriosis (69 %, 95% CI 58-79%) had the 4G/4G genotype compared with only 5 of 43 (12%; 95% CI 4-25%) controls. In contrast, the 5G/5G genotype associated with normal fibrinolysis was found in 2 of 75 (3%; 95% CI 0-9%) women with endometriosis compared with 24 of 43 (56%; 95% CI 40-71%) controls.. Hypofibrinolysis, associated with the 4G allele of the PAI-1 gene, was found significantly more often in women with endometriosis compared with controls. Persistence of fibrin matrix could support the initiation of endometriotic lesions in the peritoneal cavity, explaining why some women with retrograde menstruation develop endometriosis while others do not.. II-2.

    Topics: Adult; Alleles; Endometriosis; Female; Fibrin; Fibrinolysis; Genetic Variation; Genotype; Humans; Infertility; Multivariate Analysis; Pain; Plasminogen Activator Inhibitor 1; Polymerase Chain Reaction; Polymorphism, Genetic

2006
[Detection of tumor markers in uterine cancer (plasminogen activators, plasminogen activator inhibitors) using fibrin autography].
    Nihon Sanka Fujinka Gakkai zasshi, 1992, Volume: 44, Issue:10

    Topics: Adenocarcinoma; Biomarkers, Tumor; Electrophoresis, Polyacrylamide Gel; Endometriosis; Female; Fibrin; Humans; Plasminogen Inactivators; Tissue Plasminogen Activator; Urokinase-Type Plasminogen Activator; Uterine Cervical Neoplasms; Uterine Neoplasms

1992